Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Alexion Pharm Inc (ALXN)

Alexion Pharm Inc (ALXN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 28,063,258
  • Shares Outstanding, K 224,237
  • Annual Sales, $ 4,131 M
  • Annual Income, $ 77,600 K
  • 60-Month Beta 1.58
  • Price/Sales 6.89
  • Price/Cash Flow 14.05
  • Price/Book 2.93

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate 2.12
  • Number of Estimates 8
  • High Estimate 2.26
  • Low Estimate 2.01
  • Prior Year 1.88
  • Growth Rate Est. (year over year) +12.77%

Price Performance

See More
Period Period Low Period High Performance
1-Month
112.86 +11.06%
on 05/31/19
132.77 -5.60%
on 06/24/19
-1.81 (-1.42%)
since 05/24/19
3-Month
112.86 +11.06%
on 05/31/19
141.86 -11.65%
on 04/10/19
-11.45 (-8.37%)
since 03/26/19
52-Week
92.56 +35.41%
on 12/24/18
141.86 -11.65%
on 04/10/19
+2.91 (+2.38%)
since 06/26/18

Most Recent Stories

More News
Biotech Stock Roundup: Vertex, AMAG Drugs Get FDA Nod, Conatus Study Fails & More

Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.

CNAT : 0.28 (-2.45%)
VRTX : 177.66 (-1.38%)
GILD : 66.68 (-2.63%)
AMAG : 9.23 (+4.06%)
REGN : 305.08 (-2.50%)
ALXN : 125.34 (+0.15%)
Alexion's sBLA for Ultomiris Gets Priority Review From FDA

The FDA accepts Alexion's (ALXN) sBLA for Ultomiris under priority review for treating atypical hemolytic uremic syndrome to inhibit complement-mediated thrombotic microangiopathy. Shares increase.

AKTX : 2.01 (-3.37%)
ACHN : 2.68 (-1.47%)
ACOR : 6.93 (-1.84%)
ALXN : 125.34 (+0.15%)
3 Big Biotechs Hold Growth Potential in Second Half of 2019

We highlight a few leading players from the biotech sector, having surpassed the same so far in 2019 and are likely to put up a good show during the second half of 2019 as well.

CELG : 92.41 (-0.84%)
ARRY : 46.12 (-0.19%)
VRTX : 177.66 (-1.38%)
GILD : 66.68 (-2.63%)
BMY : 44.92 (-1.86%)
ALXN : 125.34 (+0.15%)
Oracle, Noble Energy rise while Carnival, Steelcase fall

NEW YORK (AP) — Stocks that moved substantially or traded heavily on Thursday:

SCS : 16.10 (+0.75%)
NBL : 21.77 (+2.74%)
TYPE : 16.78 (-1.00%)
CCL : 45.38 (-0.15%)
ALXN : 125.34 (+0.15%)
U.S. FDA Accepts Supplemental Biologics License Application (sBLA) for ULTOMIRIS(R) (ravulizumab-cwvz) under Priority Review for the Treatment of Atypical Hemolytic Uremic Syndrome (aHUS)

SOURCE: Alexion Pharmaceuticals, Inc.

ALXN : 125.34 (+0.15%)
Is Alexion (ALXN) a Solid Growth Stock? 3 Reasons to Think " Yes "

Alexion (ALXN) could produce exceptional returns because of its solid growth attributes.

ALXN : 125.34 (+0.15%)
5 Best-Performing Summer Stocks to Add to Your Watch List

We highlight five stocks that tend to do well during summer, the period between the Memorial Day and the Labor Day.

GOOGL : 1,080.32 (-0.67%)
NVDA : 159.26 (+5.14%)
AAPL : 199.80 (+2.16%)
COO : 328.43 (-0.47%)
FB : 187.66 (-0.62%)
AMZN : 1,897.83 (+1.04%)
ALXN : 125.34 (+0.15%)
Alexion (ALXN) Stock Up 30.7% YTD: Will the Momentum Stay?

Alexion (ALXN) gains 30.7% on solid performance of lead drug Soliris and approval of Ultomiris.

CELG : 92.41 (-0.84%)
GILD : 66.68 (-2.63%)
HALO : 16.32 (+0.25%)
ALXN : 125.34 (+0.15%)
3 Reasons Growth Investors Will Love Alexion (ALXN)

Alexion (ALXN) could produce exceptional returns because of its solid growth attributes.

ALXN : 125.34 (+0.15%)
SmarTrend Watching for Potential Pullback in Shares of Alexion Pharm After 2.31% Gain

Alexion Pharm (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $130.77 to a high of $131.43. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of...

ALXN : 125.34 (+0.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade ALXN with:

Business Summary

Alexion Pharmaceuticals, Inc. is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the innovation, development and commercialization of life-changing therapies. Alexion is the global leader in complement inhibition and has developed and commercializes...

See More

Key Turning Points

2nd Resistance Point 128.70
1st Resistance Point 127.02
Last Price 125.34
1st Support Level 123.38
2nd Support Level 121.42

See More

52-Week High 141.86
Last Price 125.34
Fibonacci 61.8% 123.03
Fibonacci 50% 117.21
Fibonacci 38.2% 111.39
52-Week Low 92.56

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar